Cancer Research and Treatment

Original Articles

Validating the Korean Geriatric Assessment Tool in Elderly Multiple Myeloma Patients: A Multicenter Study: Ji Yun Lee, Sang-A Kim, Youngil Koh, Ho-Young Yhim, Gyeong-Won Lee, Chang-Ki Min, Young Rok Do, Hyo Jung Kim, Sung Hwa Bae, Hyeon-Seok Eom, Sung-Hoon Jung, Hyunkyung Park, Seung-Hyun Nam, Ji Hyun Lee, Sung-Hyun Kim, Hyun Jung Lee, Young Seob Park, Soo-Mee Bang; Received January 15, 2025 Accepted February 20, 2025 Published online February 21, 2025; DOI: https://doi.org/10.4143/crt.2025.066 [Accepted]

Abstract PDF: Purpose
This study evaluates the Korean Cancer Study Group Geriatric Score-7 (KG-7) frailty screening tool's effectiveness in elderly multiple myeloma (MM) patients to prevent under and over-treatment.
Materials and Methods
This prospective pilot cohort study included 100 elderly patients aged 70 and older with newly diagnosed MM who had not undergone transplantation from August 2020 to January 2022.
Results
The median age was 77 years, and 73% of patients were classified at International Staging System (ISS) stages 2 or 3. Using a 5-point cutoff on the KG-7 index (non-frail, score ≥ 5; frail, score < 5), 31% were categorized as frail. After a median follow-up of 26.8 months, the 3-year overall survival rate was 73.0%. There was no statistically significant association between any frailty index and the risk of death. However, frail patients defined by the simplified frailty index (HR, 2.49; 95% CI, 1.09–5.95; p=0.030) and by KG-7 (HR, 2.43; 95% CI, 1.03–5.86; p=0.043) had a significantly higher risk of grade 3–4 non-hematologic toxicity, whereas the IMWG definition did not. Over a 24-month tracking period, vulnerability as measured by KG-7 either improved or deteriorated.
Conclusion
The pilot study, which had a limited number of participants, did not demonstrate KG-7’s effectiveness in predicting survival; however, it successfully predicted severe non-hematologic toxicities. We plan to conduct larger studies in elderly MM patients to determine whether KG-7 can help tailor their treatment regimens.

541 View
17 Download

Hematologic malignancy

Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study: Yoon Seok Choi, Joonho Shim, Ka-Won Kang, Sang Eun Yoon, Jun Sik Hong, Sung Nam Lim, Ho-Young Yhim, Jung Hye Kwon, Gyeong-Won Lee, Deok-Hwan Yang, Sung Yong Oh, Ho-Jin Shin, Hyeon-Seok Eom, Dok Hyun Yoon, Hong Ghi Lee, Seong Hyun Jeong, Won Seog Kim, Seok Jin Kim; Cancer Res Treat. 2025;57(1):267-279. Published online July 16, 2024; DOI: https://doi.org/10.4143/crt.2024.479

Abstract PDF Supplementary Material PubReader ePub: Purpose
This multicenter, open-label, phase II trial evaluated the efficacy and safety of bortezomib combined with dexamethasone for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL) in previously treated patients across 14 institutions in South Korea.
Materials and Methods
Between September 2017 and July 2020, 29 patients with histologically confirmed CTCL received treatment, consisting of eight 4-week cycles of induction therapy followed by maintenance therapy, contingent upon response, for up to one year. The primary endpoint was the proportion of patients achieving an objective global response.
Results
Thirteen of the 29 patients (44.8%) achieved an objective global response, including two complete responses. The median progression-free survival (PFS) was 5.8 months, with responders showing a median PFS of 14.0 months. Treatment-emergent adverse events were generally mild, with a low incidence of peripheral neuropathy and hematologic toxicities. Despite the trend toward shorter PFS in patients with higher mutation burdens, genomic profiling before and after treatment showed no significant emergence of new mutations indicative of disease progression.
Conclusion
This study supports the use of bortezomib and dexamethasone as a viable and safe treatment option for previously treated CTCL, demonstrating substantial efficacy and manageability in adverse effects. Further research with a larger cohort is suggested to validate these findings and explore the prognostic value of mutation profiles.

2,017 View
157 Download

Lung and Thoracic cancer

Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset: Ki Hyeong Lee, Byoung Chul Cho, Myung-Ju Ahn, Yun-Gyoo Lee, Youngjoo Lee, Jong-Seok Lee, Joo-Hang Kim, Young Joo Min, Gyeong-Won Lee, Sung Sook Lee, Kyung-Hee Lee, Yoon Ho Ko, Byoung Yong Shim, Sang-We Kim, Sang Won Shin, Jin-Hyuk Choi, Dong-Wan Kim, Eun Kyung Cho, Keon Uk Park, Jin-Soo Kim, Sang Hoon Chun, Jangyoung Wang, SeokYoung Choi, Jin Hyoung Kang; Cancer Res Treat. 2024;56(1):48-60. Published online June 27, 2023; DOI: https://doi.org/10.4143/crt.2023.453

Abstract PDF Supplementary Material PubReader ePub

Purpose
This subgroup analysis of the Korean subset of patients in the phase 3 LASER301 trial evaluated the efficacy and safety of lazertinib versus gefitinib as first-line therapy for epidermal growth factor receptor mutated (EGFRm) non–small cell lung cancer (NSCLC).
Materials and Methods
Patients with locally advanced or metastatic EGFRm NSCLC were randomized 1:1 to lazertinib (240 mg/day) or gefitinib (250 mg/day). The primary endpoint was investigator-assessed progression-free survival (PFS).
Results
In total, 172 Korean patients were enrolled (lazertinib, n=87; gefitinib, n=85). Baseline characteristics were balanced between the treatment groups. One-third of patients had brain metastases (BM) at baseline. Median PFS was 20.8 months (95% confidence interval [CI], 16.7 to 26.1) for lazertinib and 9.6 months (95% CI, 8.2 to 12.3) for gefitinib (hazard ratio [HR], 0.41; 95% CI, 0.28 to 0.60). This was supported by PFS analysis based on blinded independent central review. Significant PFS benefit with lazertinib was consistently observed across predefined subgroups, including patients with BM (HR, 0.28; 95% CI, 0.15 to 0.53) and those with L858R mutations (HR, 0.36; 95% CI, 0.20 to 0.63). Lazertinib safety data were consistent with its previously reported safety profile. Common adverse events (AEs) in both groups included rash, pruritus, and diarrhoea. Numerically fewer severe AEs and severe treatment–related AEs occurred with lazertinib than gefitinib.
Conclusion
Consistent with results for the overall LASER301 population, this analysis showed significant PFS benefit with lazertinib versus gefitinib with comparable safety in Korean patients with untreated EGFRm NSCLC, supporting lazertinib as a new potential treatment option for this patient population.

Citations

Citations to this article as recorded by

First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis
Jietao Ma, Xiaoxue Pang, Shuling Zhang, Letian Huang, Li Sun, Chengbo Han
Scientific Reports.2024;[Epub] CrossRef

6,768 View
593 Download
3 Web of Science
1 Crossref

Hematologic malignancy

Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404): Hyungwoo Cho, Dok Hyun Yoon, Dong-Yeop Shin, Youngil Koh, Sung-Soo Yoon, Seok Jin Kim, Young Rok Do, Gyeong-Won Lee, Jae-Yong Kwak, Yong Park, Min Kyoung Kim, Hye Jin Kang, Jun Ho Yi, Kwai Han Yoo, Won Sik Lee, Byeong Bae Park, Jae Cheol Jo, Hyeon-Seok Eom, Hyo Jung Kim, Seong Hyun Jeong, Young-Woong Won, Byeong Seok Sohn, Ji-Hyun Kwon, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2023;55(2):684-692. Published online January 2, 2023; DOI: https://doi.org/10.4143/crt.2022.1434

Abstract PDF Supplementary Material PubReader ePub

Purpose
We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients.
Materials and Methods
Patients with PTCL receiving chemotherapy with curative intent were registered and prospectively monitored. All patients were pathologically diagnosed with PTCL.
Results
A total of 191 patients with PTCL were enrolled in this prospective registry study. PTCL, not otherwise specified (PTCL-NOS) was the most common pathologic subtype (n=80, 41.9%), followed by angioimmunoblastic T-cell lymphoma (AITL) (n=60, 31.4%). With a median follow-up duration of 3.9 years, the 3-year progression-free survival (PFS) and overall survival (OS) rates were 39.5% and 60.4%, respectively. The role of upfront ASCT was evaluated in patients who were considered transplant-eligible (n=59). ASCT was performed as an upfront consolidative treatment in 32 (54.2%) of these patients. There were no significant differences in PFS and OS between the ASCT and non-ASCT groups for all patients (n=59) and for patients with PTCL-NOS (n=26). However, in patients with AITL, the ASCT group was associated with significantly better PFS than the non-ASCT group, although there was no significant difference in OS.
Conclusion
The current study demonstrated that the survival outcomes with the current treatment options remain poor for patients with PTCL-NOS. Upfront ASCT may provide a survival benefit for patients with AITL, but not PTCL-NOS.

Citations

Citations to this article as recorded by

Successful Treatment, with Chemotherapy and Intravenous Administration of Ascorbic Acid, of a Patient with Peripheral T-Cell Lymphoma, Not Otherwise Specified
Chiaki Tokoro, Atsushi Tashiro, Kenji Ina, Yoshiteru Tanaka, Hiroyuki Kobayakawa, Takashi Yoshida, Satoshi Kayukawa
Journal of Cancer Research Updates.2024; 13: 1. CrossRef
Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis
L. Girard, Y. J. Koh, L. P. Koh, Y. L. Chee, H. L. Chan, J. Lee, S. de Mel, L. M. Poon, M. Samuel
Bone Marrow Transplantation.2024; 59(6): 838. CrossRef
Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances
Luís Alberto de Pádua Covas Lage, Hebert Fabricio Culler, Cadiele Oliana Reichert, Sheila Aparecida Coelho da Siqueira, Juliana Pereira
Frontiers in Oncology.2023;[Epub] CrossRef
Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma
Qingyang Zhang, Le Yin, Qinqiao Lai, Yan Zhao, Hongling Peng
Clinical and Experimental Medicine.2023; 23(8): 4219. CrossRef

5,638 View
207 Download
3 Web of Science
4 Crossref

Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts: Jun Ho Yi, Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Youngil Koh, Jin Seok Kim, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Whan Jung Yun, Yong Park, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Dae-Sik Hong, Ho-Sup Lee, Gyeong-Won Lee, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2023;55(1):325-333. Published online April 22, 2022; DOI: https://doi.org/10.4143/crt.2022.008

Abstract PDF PubReader ePub

Purpose
Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%-50% of patients will eventually have relapsed or refractory disease, whose prognosis is extremely dismal.
Materials and Methods
We have carried out two prospective cohort studies that include over 1,500 DLBCL patients treated with rituximab plus CHOP (#NCT01202448 and #NCT02474550). In the current report, we describe the outcomes of refractory DLBCL patients. Patients were defined to have refractory DLBCL if they met one of the followings, not achieving at least partial response after 4 or more cycles of R-CHOP; not achieving at least partial response after 2 or more cycles of salvage therapy; progressive disease within 12 months after autologous stem cell transplantation.
Results
Among 1,581 patients, a total of 260 patients met the criteria for the refractory disease after a median time to progression of 9.1 months. The objective response rate of salvage treatment was 26.4%, and the complete response rate was 9.6%. The median overall survival (OS) was 7.5 months (95% confidence interval, 6.4 to 8.6), and the 2-year survival rate was 22.1%±2.8%. The median OS for each refractory category was not significantly different (p=0.529).
Conclusion
In line with the previous studies, the outcomes of refractory DLBCL patients were extremely poor, which necessitates novel approaches for this population.

Citations

Citations to this article as recorded by

PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
Peng Sun, Hong Cen, Haiyan Yang, Rui Huang, Zhen Cai, Xuekui Gu, Hanying Bao, Zusheng Xu, Zuhong Xu, Zhi-Ming Li
Cancer Cell International.2025;[Epub] CrossRef
Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia
Ya Hwee Tan, Dok Hyun Yoon, Andrew J. Davies, Christian Buske, Yang Liang Boo, Nagavalli Somasundaram, Francesca Lim, Shin Yeu Ong, Anand Jeyasekharan, Koji Izutsu, Won Seog Kim, Jason Yongsheng Chan
Discover Oncology.2025;[Epub] CrossRef
Recent advances in cellular immunotherapy for lymphoid malignancies
Haerim Chung, Hyunsoo Cho
Blood Research.2023; 58(4): 166. CrossRef
Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases
Hongyu Chen, Junmin Wang, Caiyun Zhang, Peilun Ding, Shuxia Tian, Junming Chen, Guang Ji, Tao Wu
Biomedicine & Pharmacotherapy.2022; 153: 113341. CrossRef

7,815 View
358 Download
3 Web of Science
4 Crossref

Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study: Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Yong Park, Hye Jin Kang, Youngil Koh, Gyeong-Won Lee, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Hwan Jung Yun, Jun Ho Yi, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Shin Young Hyun, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Se-Hyung Kim, Ho-Sup Lee, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2022;54(4):1268-1277. Published online December 30, 2021; DOI: https://doi.org/10.4143/crt.2021.1168

Abstract PDF Supplementary Material PubReader ePub: Purpose
Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP).
Materials and methods
We conducted a prospective cohort study to evaluate the effectiveness of pegfilgrastim prophylaxis in DLBCL patients receiving R-CHOP, and we compared them with the PROCESS cohort (n=485).
Results
Since January 2015, 986 patients with DLBCL were enrolled. Pegfilgrastim was administered at least once in 930 patients (94.3%), covering 90.3% of all cycles. FN developed in 137 patients (13.9%) in this cohort (23.7% in the PROCESS cohort, p<0.001), and 4.2% of all cycles (10.2% in the PROCESS cohort, p<0.001). Dose delay was less common (≥3 days: 18.1% vs. 23.7%, p=0.015; ≥5 days: 12.0% vs. 18.3%, p=0.023) in this cohort than in the PROCESS cohort. The incidence of TRM (3.2% vs. 5.6%, p=0.047) and infection-related death (1.8% vs. 4.5%, p=0.004) was lower in this cohort than in the PROCESS cohort. The 4-year overall survival (OS) and progression-free survival (PFS) rates of the two cohorts were not different (OS: 73.0% vs. 71.9%, p=0.545; PFS: 69.5% vs. 68.8%, p=0.616). However, in patients aged ≥75 years, the 4-year OS and PFS rates were higher in this cohort than in the PROCESS cohort (OS: 49.6% vs. 33.7%, p=0.032; PFS: 44.2% vs. 30.3% p=0.047).
Conclusion
Pegfilgrastim prophylaxis is effective in the prevention of FN and infection-related death in DLBCL patients receiving R-CHOP, and it also improves OS in patients aged ≥75 years.

8,013 View
299 Download
1 Web of Science

Case Report

Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report: Haa-Na Song, Min Gyu Kang, Jeong Rang Park, Jin-Yong Hwang, Jung Hun Kang, Won Seop Lee, Gyeong-Won Lee; Cancer Res Treat. 2018;50(4):1458-1461. Published online January 22, 2018; DOI: https://doi.org/10.4143/crt.2017.529

Abstract PDF PubReader ePub

Myxofibrosarcoma is a rare tumor, refractory to cytotoxic chemotherapy and radiotherapy. Pembrolizumab is an innovative immunotherapy drug consisting of programmed death receptor ligand 1 antibody proven to be useful for numerous types of cancer cells. A patient had been diagnosed with metastatic myxofibrosarcoma, refractory to radiotherapy and conventional cytotoxic chemotherapy. The patient achieved a partial response during palliative chemotherapy with pembrolizumab for 14 cycles. To the best of our knowledge, this is the first case report demonstrating the efficacy of pembrolizumab for refractory myxofibrosarcoma.

Citations

Citations to this article as recorded by

Pembrolizumab and radiation therapy for multifocal myxofibrosarcoma of the scalp: a case report
Christopher Ryan Grant, Zhaohui Arter, Janellen Smith, Steven N. Seyedin, Mahra Nourbakhsh, Bonnie Lee, Andrew Creadore, Nataliya Mar
Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Microsatellite Instability and Clinical Use in Sarcomas: Systematic Review and Illustrative Case Report
Italo Fernandes, Douglas Dias e Silva, Vanderlei Segatelli, Renée Zon Filippi, Ana Carolina de Rezende, Paulo Campregher, Fernando Moura, Reynaldo Jesus-Garcia, Roberto Carmagnani Pestana
JCO Precision Oncology.2024;[Epub] CrossRef
Current Landscape of Immunotherapy for Advanced Sarcoma
Víctor Albarrán, María Luisa Villamayor, Javier Pozas, Jesús Chamorro, Diana Isabel Rosero, María San Román, Patricia Guerrero, Patricia Pérez de Aguado, Juan Carlos Calvo, Coral García de Quevedo, Carlos González, María Ángeles Vaz
Cancers.2023; 15(8): 2287. CrossRef
Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing?
Enrico Lucarelli, Alessandro De Vita, Chiara Bellotti, Tommaso Frisoni, Silvia Vanni, Ania Naila Guerrieri, Micaela Pannella, Laura Mercatali, Marco Gambarotti, Serena Duchi, Giacomo Miserocchi, Margherita Maioli, Chiara Liverani, Toni Ibrahim
Cancers.2023; 15(21): 5132. CrossRef
Pd-1, Pd-L1, Ido, Cd70 and Microsatellite Instability as Potential Targets to Prevent Immune Evasion in Sarcomas
Vasiliki Siozopoulou, Evelien Smits, Karen Zwaenepoel, Jimmy Liu, Abraham Pouliakis, Patrick A Pauwels, Elly Marcq
Immunotherapy.2023; 15(15): 1257. CrossRef
Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study
Mauricio Fernando Ribeiro, Hagit Peretz Soroka, Zainab Bhura, Ian Hirsch, Jay Wunder, Peter Ferguson, Kim Tsoi, Savtaj Brar, Rebecca Gladdy, Carol Swallow, Peter Chung, Charles Catton, Philip Wong, Geoffrey Watson, Albiruni Ryan Abdul Razak, Abha A. Gupta
Therapeutic Advances in Medical Oncology.2023;[Epub] CrossRef
Biology and Management of High-Grade Myxofibrosarcoma: State of the Art and Future Perspectives
Jun Nishio, Shizuhide Nakayama
Diagnostics.2023; 13(19): 3022. CrossRef
Targeted therapies and checkpoint inhibitors in sarcoma
M Vasella, E Gousopoulos, M Guidi, G Storti, S Y Song, G Grieb, C Pauli, N Lindenblatt, P Giovanoli, B -S Kim
QJM: An International Journal of Medicine.2022; 115(12): 793. CrossRef
Gemcitabine-Containing Chemotherapy for the Treatment of Metastatic Myxofibrosarcoma Refractory to Doxorubicin: A Case Series
Arielle Elkrief, Suzanne Kazandjian, Thierry Alcindor
Current Oncology.2021; 28(1): 813. CrossRef
Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient
Yi Luo, Li Min, Yong Zhou, Fan Tang, Minxun Lu, Hongmei Xie, Yitian Wang, Hong Duan, Wenli Zhang, Chongqi Tu
Medicine.2021; 100(12): e25262. CrossRef
Is immunotherapy in the future of therapeutic management of sarcomas?
Ottavia Clemente, Alessandro Ottaiano, Giuseppe Di Lorenzo, Alessandra Bracigliano, Sabrina Lamia, Lucia Cannella, Antonio Pizzolorusso, Massimiliano Di Marzo, Mariachiara Santorsola, Annarosaria De Chiara, Flavio Fazioli, Salvatore Tafuto
Journal of Translational Medicine.2021;[Epub] CrossRef
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS – GROUP). Part I
Javier Martínez-Trufero, Josefina Cruz Jurado, M.Carmen Gómez-Mateo, Daniel Bernabeu, Luis Javier Floría, Javier Lavernia, Ana Sebio, Xavier García del Muro, Rosa Álvarez, Raquel Correa, C.Nieves Hernández-León, Gloria Marquina, Nadia Hindi, Andrés Redond
Cancer Treatment Reviews.2021; 99: 102259. CrossRef
Myxofibrosarcoma harboring an MLH1 pathogenic germline variant associated with Muir-Torre syndrome: a case report
Makoto Nakagawa, Eisuke Kobayashi, Masayoshi Yamada, Tomoko Watanabe, Makoto Hirata, Noriko Tanabe, Mineko Ushiama, Hiromi Sakamoto, Chiaki Sato, Taisuke Mori, Akihiko Yoshida, Teruhiko Yoshida, Kokichi Sugano, Akira Kawai
Hereditary Cancer in Clinical Practice.2021;[Epub] CrossRef
A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model
Tasuku Kiyuna, Yasunori Tome, Takashi Murakami, Kentaro Miyake, Kentaro Igarashi, Kei Kawaguchi, Hiromichi Oshiro, Takashi Higuchi, Masuyo Miyake, Norihiko Sugisawa, Zhiying Zhang, Sahar Razmjooei, Sintawat Wangsiricharoen, Bartosz Chmielowski, Scott D. N
Biochemical and Biophysical Research Communications.2018; 505(3): 733. CrossRef

12,875 View
345 Download
15 Web of Science
14 Crossref

Original Articles

Population-Based Regional Cancer Incidence in Korea: Comparison between Urban and Rural Areas: Haa-Na Song, Se-Il Go, Won Sup Lee, Yire Kim, Hye Jung Choi, Un Seok Lee, Myoung Hee Kang, Gyeong-Won Lee, Hoon-Gu Kim, Jung Hun Kang, Yune Sik Kang, Jeong-Hee Lee, Jin-Myung Jung, Soon Chan Hong; Cancer Res Treat. 2016;48(2):789-797. Published online July 14, 2015; DOI: https://doi.org/10.4143/crt.2015.062

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to investigate differences in organ-specific cancer incidence according to the region and population size in Korea.
Materials and Methods
We reviewed the data of the cancer registration program of Gyeongnam Regional Cancer Center between 2008 and 2011. Age-standardized rates of cancer incidence were analyzed according to population size of the region and administrative zone.
Results
Incidence of thyroid cancer has been increasing rapidly in both urban and rural areas. However, the thyroid cancer incidence was much lower in rural areas than in urban areas and megalopolis such as Seoul. Gastric cancer was relatively more common in rural areas, in megalopolis near the sea (Ulsan, Busan, and Incheon), and other southern provinces (Chungcheongnam-do, Gyeongsangbuk-do, and Gyeongsangnam-do). A detailed analysis in Gyeongsangnam-do revealed that rural areas have relatively low incidence of thyroid and colorectal cancer, and relatively high incidence of gastric and lung cancer compared to urban areas.
Conclusion
This study suggests that there are some differences in cancer incidence by population size. Thyroid and colorectal cancer incidence was increasing, and gastric and lung cancer was slightly decreasing in urban areas, whereas gastric and lung cancer incidence still remains high in rural areas.

Citations

Citations to this article as recorded by

Impact of regional medical self-sufficiency on mortality from cancer, stroke and myocardial infarction
Il Yun, Jong Youn Moon
Public Health.2025; 238: 59. CrossRef
Projection of future gastric cancer incidence and health‐care service demand by geographic area in Kanagawa, Japan
Choy‐Lye Chei, Sho Nakamura, Kaname Watanabe, Ryo Watanabe, Akio Kurokawa, Taizo Iwane, Sayaka Itoh, Hiroto Narimatsu
Cancer Science.2025; 116(2): 488. CrossRef
Preliminary reports of lung cancer screening with low-dose computed tomography: a nationwide performance on the Korean population in 2019–2020
Horim A. Hwang, Dong Jun Kim, Nan-He Yoon, Jae Kwan Jun, Mina Suh, Sunhwa Lee, Seongju Kim, Seung Eun Jung, Hooyeon Lee
European Radiology.2025;[Epub] CrossRef
Rural-urban disparity in cancer burden and care: findings from an Indian cancer registry
Divya Khanna, Priyanka Sharma, Atul Budukh, Rajesh Vishwakarma, Anand N. Sharma, Sonali Bagal, Varsha Tripathi, Vijay Kumar Maurya, Pankaj Chaturvedi, Satyajit Pradhan
BMC Cancer.2024;[Epub] CrossRef
What is the relationship between the local population change and cancer incidence in patients with dyslipidemia: Evidence of the impact of local extinction in Korea
Wonjeong Jeong, Dong‐Woo Choi, Woorim Kim, Kyu‐Tae Han
Cancer Medicine.2024;[Epub] CrossRef
Health expenditure trajectory and gastric cancer incidence in the National Health Insurance Senior Cohort: a nested case-control study
Woo-Ri Lee, Ki-Bong Yoo, Jin-Won Noh, Minjee Lee
BMC Health Services Research.2024;[Epub] CrossRef
Urban Scaling of Health Outcomes: a Scoping Review
Edwin M. McCulley, Pricila H. Mullachery, Ana F. Ortigoza, Daniel A. Rodríguez, Ana V. Diez Roux, Usama Bilal
Journal of Urban Health.2022; 99(3): 409. CrossRef
Loss of Novel Diversity in Human Gut Microbiota Associated with Ongoing Urbanization in China
Shan Sun, Huijun Wang, Annie Green Howard, Jiguo Zhang, Chang Su, Zhihong Wang, Shufa Du, Anthony A. Fodor, Penny Gordon-Larsen, Bing Zhang, Emily B. Graham
mSystems.2022;[Epub] CrossRef
Deciphering the impact of urban built environment density on respiratory health using a quasi-cohort analysis of 5495 non-smoking lung cancer cases
Lan Wang, Wenyao Sun, Anne Vernez Moudon, Yong-Guan Zhu, Jinfeng Wang, Pingping Bao, Xiaojing Zhao, Xiaoming Yang, Yinghui Jia, Surong Zhang, Shuang Wu, Yuxi Cai
Science of The Total Environment.2022; 850: 158014. CrossRef
Difference in medical service use among Korean gastric cancer survivors according to regional healthcare vulnerabilities: a cohort study
Sung Hoon Jeong, Jae Hong Joo, Minah Park, Choa Yun, Soo Hyun Kang, Eun-Cheol Park, Yoon Dae Han, Sung-In Jang
Supportive Care in Cancer.2022; 30(11): 9233. CrossRef
Apoptotic Effects of Anthocyanins from Vitis coignetiae Pulliat Are Enhanced by Augmented Enhancer of the Rudimentary Homolog (ERH) in Human Gastric Carcinoma MKN28 Cells
Cheol Park, Won Sup Lee, Se-Il Go, Sang-Ho Jeong, Jiyun Yoo, Hee-Jae Cha, Young-Joon Lee, Heui-Soo Kim, Sun-Hee Leem, Hye Jung Kim, Gon Sup Kim, Soon-Chan Hong, Yung Hyun Choi
International Journal of Molecular Sciences.2021; 22(6): 3030. CrossRef
Current therapeutic options for gastric adenocarcinoma
C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
Impact of Rurality on National Trends in Thyroid Cancer Incidence and Long‐Term Survival
Alexandria D. McDow, Whitney E. Zahnd, Peter Angelos, John D. Mellinger, Sabha Ganai
The Journal of Rural Health.2020; 36(3): 326. CrossRef
Predicted Future Mortality Attributed to Increases in Temperature and PM10 Concentration under Representative Concentration Pathway Scenarios
Jiyun Jung, Jae Young Lee, Hyewon Lee, Ho Kim
International Journal of Environmental Research and Public Health.2020; 17(7): 2600. CrossRef
Polyphenols Extracted from Artemisia annua L. Exhibit Anti-Cancer Effects on Radio-Resistant MDA-MB-231 Human Breast Cancer Cells by Suppressing Stem Cell Phenotype, β-Catenin, and MMP-9
Young Shin Ko, Eun Joo Jung, Se-il Go, Bae Kwon Jeong, Gon Sup Kim, Jin-Myung Jung, Soon Chan Hong, Choong Won Kim, Hye Jung Kim, Won Sup Lee
Molecules.2020; 25(8): 1916. CrossRef
Temporal and geographical variations in colorectal cancer incidence in Northern Iran 2004–2013
Susan Hasanpour-Heidari, Abdolreza Fazel, Shahryar Semnani, Seyyed-Reza Khandoozi, Taghi Amiriani, SeyedMehdi Sedaghat, Reza Hosseinpoor, Ramin Azarhoush, Mohammad Poorabbasi, Mohammad Naeimi-Tabiei, Gholamreza Roshandel, Freddie Bray, Elisabete Weiderpas
Cancer Epidemiology.2019; 59: 143. CrossRef
Regional Differences in Years of Life Lost in Korea from 1997 to 2015
Dun-Sol Go, Young-Eun Kim, Munkhzul Radnaabaatar, Yunsun Jung, Jaehun Jung, Seok-Jun Yoon
Journal of Korean Medical Science.2019;[Epub] CrossRef
Morin enhances auranofin anticancer activity by up‐regulation of DR4 and DR5 and modulation of Bcl‐2 through reactive oxygen species generation in Hep3B human hepatocellular carcinoma cells
Hyun Hwang‐Bo, Won Sup Lee, Arulkumar Nagappan, Hong Jae Kim, Radha Panchanathan, Cheol Park, Seong‐Hwan Chang, Nam Deuk Kim, Sun‐Hee Leem, Young‐Chae Chang, Taeg Kyu Kwon, Jae Hun Cheong, Gon Sup Kim, Jin‐Myung Jung, Sung Chul Shin, Soon Chan Hong, Yung
Phytotherapy Research.2019; 33(5): 1384. CrossRef
The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer
Se-Il Go, Gyung Hyuck Ko, Won Sup Lee, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha
Cancer Research and Treatment.2019; 51(4): 1411. CrossRef
Cancer Incidence Trend in the Hebei Spirit Oil Spill Area, from 1999 to 2014: An Ecological Study
Kyung-Hwa Choi, Myung-Sook Park, Mina Ha, Jong-Il Hur, Hae-Kwan Cheong
International Journal of Environmental Research and Public Health.2018; 15(5): 1006. CrossRef
Gut Microbiota in Tibetan Herdsmen Reflects the Degree of Urbanization
Huan Li, Tongtong Li, Xiangzhen Li, Guanhong Wang, Qiang Lin, Jiapeng Qu
Frontiers in Microbiology.2018;[Epub] CrossRef
Regional Differences in Years of Life Lost in Korea from 1997 to 2015
Dun-Sol Go, Young-Eun Kim, Munkhzul Radnaabaatar, Yunsun Jung, Jaehun Jung, Seok-Jun Yoon
Journal of Korean Medical Science.2018;[Epub] CrossRef
Estimation of the Incidence of Hepatocellular Carcinoma and Cholangiocarcinoma in Songkhla, Thailand, 1989-2013, Using Multiple Imputation Method
Seesai Yeesoonsang, Surichai Bilheem, Edward McNeil, Sophon Iamsirithaworn, Chuleeporn Jiraphongsa, Hutcha Sriplung
Cancer Research and Treatment.2017; 49(1): 54. CrossRef
Prognostic impact of Ki-67 in patients with gastric cancer—the importance of depth of invasion and histologic differentiation
Gyung Hyuck Ko, Se-Il Go, Won Sup Lee, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha
Medicine.2017; 96(25): e7181. CrossRef
Recent urbanization in China is correlated with a Westernized microbiome encoding increased virulence and antibiotic resistance genes
Kathryn Winglee, Annie Green Howard, Wei Sha, Raad Z. Gharaibeh, Jiawu Liu, Donghui Jin, Anthony A. Fodor, Penny Gordon-Larsen
Microbiome.2017;[Epub] CrossRef

13,180 View
111 Download
26 Web of Science
25 Crossref

Chemotherapy in Advanced Gastric Cancer Patients Associated with Disseminated Intravascular Coagulation: In Gyu Hwang, Jin Hwa Choi, Se Hoon Park, Sung Yong Oh, Hyuk-Chan Kwon, Soon Il Lee, Do Hyoung Lim, Gyeong-Won Lee, Jung Hun Kang; Cancer Res Treat. 2014;46(1):27-32. Published online January 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.1.27

Abstract PDF PubReader ePub

PURPOSE
Little is known about the clinical features of advanced gastric cancer (AGC) combined with disseminated intravascular coagulation (DIC). The main objective of this study was to determine the clinical outcome of patients with AGC complicated by DIC.
MATERIALS AND METHODS
We conducted a retrospective review of 68 AGC patients diagnosed with DIC at four tertiary medical centers between January 1995 and June 2010.
RESULTS
Sixty eight patients were included. The median age was 55 years (range, 25 to 78 years). Nineteen patients received chemotherapy, whereas 49 patients received only best supportive care (BSC). The median overall survival (OS) of the 68 patients was 16 days (95% confidence interval [CI], 11 to 21 days). Significantly prolonged OS was observed in the chemotherapy group, with a median survival of 61 days compared to 9 days in the BSC group (p<0.001, log-rank test). Age and previous chemotherapy were another significant factors that were associated with OS in univariate analysis. In multivariate analysis, age (> or =65 vs. <65; hazard ratio [HR], 0.38; 95% CI, 0.18 to 0.78; p<0.001), chemotherapy (BSC vs. chemotherapy; HR 0.31; 95% CI, 0.15 to 0.63; p<0.001), and previous chemotherapy (yes or no; HR, 0.49; 95% CI, 0.25 to 0.98; p<0.045) were consistently independent prognostic factors that impacted OS.
CONCLUSION
Our study showed that patients with AGC complicated by DIC had very poor OS, and suggested that chemotherapy might improve OS of these patients.

Citations

Citations to this article as recorded by

Long-term survival of a patient with gastric cancer with bone marrow metastasis receiving S-1 plus oxaliplatin beyond three years: a case report and literature review
Hirotaka Suto, Yumiko Inui, Atsuo Okamura
Frontiers in Oncology.2024;[Epub] CrossRef
Metastatic gastric adenocarcinoma discovered in the bone marrow
Ekaterina Proskuriakova, Vaisny Balamurali, Anuradha Hooda, Paramjeet Khosla
BMJ Case Reports.2024; 17(9): e260217. CrossRef
Case report: PD-1 inhibitor-based treatment strategies in gastric cancer complicated by bone marrow metastasis and disseminated intravascular coagulation: A report of two cases
Ren-Ze Huang, Nuo Chen, Yan Hu, Wan-Ming Hu, Feng-Hua Wang, Dong-Liang Chen
Frontiers in Oncology.2023;[Epub] CrossRef
Comparative analysis of systemic oncological treatments and best supportive care for advanced gastresophageal cancer: A comprehensive scoping review and evidence map
Santero Marilina, Meade Adriana, Selva Anna, Acosta‐Dighero Roberto, Meza Nicolás, Quintana Maria Jesús, Bracchiglione Javier, Requeijo Carolina, Salazar Josefina, Rodríguez Grijalva Gerardo, Solà Ivan, Urrútia Gerard, Bonfill Cosp Xavier
Journal of Evidence-Based Medicine.2023; 16(2): 216. CrossRef
Clinicopathologic features and prognosis of 71 patients with gastric cancer and disseminated intravascular coagulation
Ling Chen, Jing Lin, Yu Chen, Jiami Yu, Xiaojie Wang
PeerJ.2023; 11: e16527. CrossRef
Docetaxel and Fluorouracil as First-Line Therapy for Gastric Cancer with Bone Marrow Metastasis and Disseminated Intravascular Coagulation
Zhai Xiaohui, Li Shanshan, Cao Taiyuan, Du Ge, Yu Hongen, Shi Lishuo, Lin Xiaoru, Hong Wanjia, Xiao Jian
Future Oncology.2022; 18(35): 3875. CrossRef
A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms
Mayu Kobayashi, Hideo Wada, Shunsuke Fukui, Hiroki Mizutani, Yuhuko Ichikawa, Katsuya Shiraki, Isao Moritani, Hidekazu Inoue, Motomu Shimaoka, Hideto Shimpo
Journal of Clinical Medicine.2021; 10(22): 5352. CrossRef
Understanding and treating solid tumor–related disseminated intravascular coagulation in the “era” of targeted cancer therapies
Felice Vito Vitale, Giuseppe SA Longo-Sorbello, Stefano Rotondo, Francesco Ferrau
SAGE Open Medicine.2017;[Epub] CrossRef
Advanced gastric cancer linitis plastica presented with disseminated intravascular coagulation
Sehem Ghazala, Jawad Bilal, Irbaz Bin Riaz
BMJ Case Reports.2016; 2016: bcr2016217675. CrossRef
Efficacy and Safety of Weekly Paclitaxel Therapy for Advanced Gastric Cancer Patients with Disseminated Intravascular Coagulation
Sadayuki Kawai, Yasuhiro Sakamoto, Yoshikazu Takahashi, Sonoko Ichikawa, Makio Gamoh
Journal of Gastrointestinal Cancer.2015; 46(4): 438. CrossRef
D-Dimer Can Serve as a Prognostic and Predictive Biomarker for Metastatic Gastric Cancer Treated by Chemotherapy
Se-Il Go, Min Jeong Lee, Won Sup Lee, Hye Jung Choi, Un Seok Lee, Rock Bum Kim, Myoung Hee Kang, Hoon-Gu Kim, Gyeong-Won Lee, Jung Hun Kang, Jeong-Hee Lee, Sun Joo Kim
Medicine.2015; 94(30): e951. CrossRef

14,021 View
103 Download
13 Web of Science
11 Crossref

A Phase II Trial of Haptaplatin/5-FU and Leucovorin for Advanced Stomach Cancer: Won Sup Lee, Gyeong-Won Lee, Hwal Woong Kim, Ok-Jae Lee, Young-Joon Lee, Gyung Hyuck Ko, Jong-Seok Lee, Joung Soon Jang, Woo Song Ha; Cancer Res Treat. 2005;37(4):208-211. Published online August 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.4.208

Abstract PDF PubReader ePub

Purpose

Heptaplatin (SKI-2053 R) is a new platinum analogue, with a better toxicity profile than cisplatin, and has antitumor activity even in cisplatin resistant cell lines. 5-fluoruracil (5-FU) has shown synergy with platinum compounds. This phase II trial was designed to determine the efficacy and toxicities of heptaplatin/ 5-FU (5-fluorouracil) for treating stomach cancer.

Materials and Methods

Thirty-two patients with advanced, measurable gastric adenocarcinomas were enrolled in this trial. The treatment consisted of heptaplatin, 400 mg/m²/day (1 hour IV infusion), on day 1 and 5-FU, 800 mg/m²/day (12 hours IV infusion), on days 1 to 5. The cycles were repeated every 3 weeks.

Results

Of the 26 evaluable patients, 9 had partial responses and 1a complete response (overall response rate, 38%; 95% confidence interval, 19~57%). The median response duration was 23 weeks (range: 4~60 weeks). The median time to progression was 26 weeks (range: 3~68 weeks). The grades III-IV toxicities were mostly hematological toxicities: leucopenia was observed in 11 patients (35%) and thrombocytopenia 4 (13%). No definite neuropathy was observed. Grade I-II nephropathy was also noted: grade I high BUN/creatinine levels occurred in 5 patients (16%), grade II proteinuria 2 (6%), grade I proteinuria 5 (16%). Neutropenic fever developed in 5 patients (16%) and 1 died of pneumonia in a neutropenic state.

Conclusion

This study suggests that the regimen of Heptaplatin/5-FU should be effective and have a favorable toxicity profile for the patients suffering with advanced stomach cancer.

Citations

Citations to this article as recorded by

Cisplatin Resistance in Cancer Therapy: Causes and Overcoming Strategies
S. Shruthi, K. Bhasker Shenoy
ChemistrySelect.2024;[Epub] CrossRef
Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
Dobrina Tsvetkova, Stefka Ivanova
Molecules.2022; 27(8): 2466. CrossRef
Synthesis of novel heptaplatin derivatives and evaluation of their ability to inhibit proliferation of cancer cell lines
W. Xu, D. C. Wang
Russian Journal of General Chemistry.2016; 86(4): 939. CrossRef
The extract of Paris polyphylla exerts apoptotic induction and synergic antiproliferative effect with anticancer drugs in SMMC-7721 human liver cancer cells
Jing Sun, Bao-rui Liu, Jia Wei, Xiao-ping Qian, Li-xia Yu, Ren-hua Guo, Hua Shen, Tong-shan Wang, Yong-qian Shu
Biomedicine & Preventive Nutrition.2011; 1(3): 186. CrossRef
The status of platinum anticancer drugs in the clinic and in clinical trials
Nial J. Wheate, Shonagh Walker, Gemma E. Craig, Rabbab Oun
Dalton Transactions.2010; 39(35): 8113. CrossRef
Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer
H.-C. Kwon, M.S. Roh, S.Y. Oh, S.-H. Kim, M.C. Kim, J.-S. Kim, H.-J. Kim
Annals of Oncology.2007; 18(3): 504. CrossRef

9,296 View
62 Download
6 Crossref

High-Dose Chemotherapy of Cyclophosphamide, Thiotepa and Carboplatin (CTCb) followed by Autologous Stem-Cell Transplantation as a Consolidation for Breast Cancer Patients with 10 or more Positive Lymph Nodes: a 5-Year follow-Up Results: Hee-Jung Sohn, Sang-Hee Kim, Gyeong-Won Lee, Shin Kim, Jin-Hee Ahn, Sung-Bae Kim, Sang-We Kim, Woo Kun Kim, Cheolwon Suh; Cancer Res Treat. 2005;37(3):137-142. Published online June 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.3.137

Abstract PDF PubReader ePub

Purpose

The benefit of consolidation high-dose chemotherapy (HDC) for high-risk primary breast cancer is controversial. We evaluated the efficacy and safety of consolidation HDC with cyclophosphamide, thiotepa and carboplatin (CTCb) followed by autologous stem-cell transplantation (ASCT) in resected breast cancer patients with 10 or more positive lymph nodes.

Materials and Methods

Between December 1994 and April 2000, 22 patients were enrolled. All patients received 2 to 6 cycles of adjuvant chemotherapy after surgery for breast cancer. The HDC regimen consisted of cyclophosphamide 1,500 mg/m²/day, thiotepa 125 mg/m²/day and carboplatin 200 mg/m²/day intravenous for 4 consecutive days.

Results

With a median follow-up of 58 months, 11 patients recurred and died. The median disease-free survival (DFS) and median overall survival (OS) were 49 and 69 months, respectively. The 5-year DFS and OS rates were 50% and 58%, respectively. The 12 patients with 10 to 18 involved nodes had better 5-year DFS (67%) and OS (75%) than 10 patients with more than 18 involved nodes (30% and 38%, respectively). The most common grade 3 or 4 nonhematologic toxicity was diarrhea, which occurred in 5 patients (23%). No treatment-related death was observed.

Conclusion

Consolidation HDC with CTCb followed by ASCT for resected breast cancer with more than 10 positive nodes had an acceptable toxicity but does not show promising survival.

Citations

Citations to this article as recorded by

Real-world Experience of Improvement in the Survival of Lymphoma and Myeloma Patients with Autologous Stem Cell Transplantation over a 25-year Period
Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Jung Sun Park, Cheolwon Suh
The Korean Journal of Medicine.2021; 96(6): 501. CrossRef
Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45)
X. Wang, J. Ren, J. Zhang, Y. Yan, N. Jiang, J. Yu, L. Di, G. Song, L. Che, J. Jia, X. Zhou, H. Yang, H. K. Lyerly
Clinical and Translational Oncology.2016; 18(1): 82. CrossRef

9,343 View
45 Download
2 Crossref

High-Dose Chemotherapy of Cyclophosphamide, Thiotepa, and Carboplatin (CTCb) Followed by Autologous Stem-Cell Transplantation for Metastatic Breast Cancer Patients: A 6-Year Follow-Up Result: Hee-Jung Sohn, Sang-Hee Kim, Gyeong-Won Lee, Shin Kim, Hye Jin Kang, Jin-Hee Ahn, Sung-Bae Kim, Sang-We Kim, Woo Kun Kim, Cheolwon Suh; Cancer Res Treat. 2005;37(1):24-30. Published online February 28, 2005; DOI: https://doi.org/10.4143/crt.2005.37.1.24

Abstract PDF PubReader ePub

Purpose

The benefit of high-dose chemotherapy (HDC) for metastatic breast cancer (MBC) is controversial. We evaluated the efficacy and safety of HDC with cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by autologous stem-cell transplantation (ASCT) for MBC patients.

Materials and Methods

From September 1994 to December 1999, 23 MBC patients were enrolled. All the patients received 2 to 10 cycles of induction chemotherapy. Before transplantation, 12 patients were in complete response (CR), nine were in partial response (PR), and two had progressive disease (PD). The HDC regimen consisted of cyclophosphamide 1,500 mg/m²/day, thiotepa 125 mg/m²/day and carboplatin 200 mg/m²/day intravenously for 4 consecutive days.

Results

After ASCT, 13 patients (56%) had a CR, five (22%) had a PR, three (13%) had no change, while two (9%) showed a PD. Seventeen patients relapsed or progressed during the median follow-up of 78 months. The median progression-free survival (PFS) time was 11 months and the median overall survival (OS) time was 23 months. The 5-year PFS and OS rates were 22% and 25%, respectively. On the multivariate analyses, less than 4 involved lymph nodes was predictive of a better PFS and OS.

Conclusion

HDC with CTCb for MBC has acceptable toxicity; however, this treatment does not show a survival benefit.

Citations

Citations to this article as recorded by

Real-world Experience of Improvement in the Survival of Lymphoma and Myeloma Patients with Autologous Stem Cell Transplantation over a 25-year Period
Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Jung Sun Park, Cheolwon Suh
The Korean Journal of Medicine.2021; 96(6): 501. CrossRef

9,238 View
48 Download
1 Crossref

A Phase II Trial of Docetaxel and Ifosfamide for Patients with Platinum-Resistant or Refractory Non-Small Cell Lung Cancer in a Salvage Setting: Gyeong-Won Lee, Jung-Hun Kang, Seok-Hyun Kim, Hea Yong Lee, Ho-Cheol Kim, Won-Sup Lee, Jong-Duk Lee, Young-Sil Hwang, Joung-Soon Jang, Jong-Seok Lee; Cancer Res Treat. 2004;36(5):287-292. Published online October 31, 2004; DOI: https://doi.org/10.4143/crt.2004.36.5.287

Abstract PDF PubReader ePub

Purpose

We conducted a phase II study of docetaxel and ifosfamide chemotherapy for patients with platinum-resistant or refractory non-small-cell lung cancer (NSCLC) to evaluate the response and toxicity profiles as a salvage treatment.

Materials and Methods

Between July 2000 and July 2004, 40 patients who had previously received platinum-based regimen as the first-line or second-line therapy were enrolled in this study. The treatment consisted of a docetaxel 75 mg/m² intravenous infusion on day 1 and intravenous ifosfamide 3 g/m² with Mesna® uroprotectione on day 1 through 3. This regimen was repeated every 3 weeks.

Results

One hundred thirty cycles of treatment were given, with a median of 3 cycles (range: 2~6 cycles). All the patients were evaluable for the response rate and toxicity profile. The major toxicity was myelosuppression. Grade 3~4 neutropenia occurred in 30 patients (75%) during treatment. Febrile neutropenia occurred in 16 patients (40%). Five of 40 patients (12.5%) had a partial response (95% confidence interval, 3.3~21.7%). The median time to disease progression was 2.65 months (range: 2.02~3.20 months), and the median survival was 5.24 months (range: 2.99~7.49 months).

Conclusion

Salvage chemotherapy with docetaxel and ifosfamide showed a low efficacy and a high proportion of severe neutropenia in patients with platinum-resistant or refractory advanced NSCLC.

Citations

Citations to this article as recorded by

The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m2) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated with Platinum-based Chemotherapy
Byoung Yong Shim, Chi Hong Kim, So Hyang Song, Meyung Im Ahn, Eun Jung Hong, Sung Whan Kim, Suzy Kim, Min Seop Jo, Deog Gon Cho, Kyu Do Cho, Jinyoung Yoo, Hoon-Kyo Kim
Cancer Research and Treatment.2005; 37(6): 339. CrossRef

9,702 View
52 Download
1 Crossref

First
Prev
Page of 1
Next
Last

Search